Please assess the completion status of the following clinical trial:

Trial Title: A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>/=18 years of age~* HBeAg positive chronic hepatitis B~* Compensated liver disease~Exclusion Criteria:~* Patients who had previously received treatment of drugs with activity against HBV within 6 months prior to study start~* Antiviral, anti-neoplastic or immunomodulatory treatment~* Co-infection with active hepatitis A, hepatitis C, hepatitis D, or HIV~* Evidence of decompensated liver disease~* Chronic liver disease other than viral hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).